Adams, C. E. & Eisenbruch, M. (2000) Depot fluphenazine for schizophrenia. Cochrane Library, issue 2. Oxford: Update Software
Adams, C. E., Fenton, M. K. P., Quraishi, S., et al (2001) Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry, 179, 290–299.
Anderson, D., Leadbetter, A. & Williams, B. (1989) In defence of the depot clinic. The consumers' opinion. Psychiatric Bulletin, 13, 177–179.
Barnes, T. R. E. & Curson, D. A. (1994) Long term depot antipsychotics. A risk–benefit assessment. Drug Safety, 10, 464–479.
Bennett, J., Done, J. & Hunt, B. (1995) Assessing the side-effects of antipsychotic drugs: a survey of CPN practice. Journal of Psychiatric and Mental Health Nursing, 2, 177–182.
Brooker, C., Faugier, J. & Gray, C. (1996) An Audit of Depot Clinics in the North West Region.
Sheffield: University of Sheffield/NHS Executive N. W Regional Office.
Buis, W. (1992) Patients' opinions concerning side effects of depots neuroleptics. American Journal of Psychiatry, 149, 844–845.
Burns, T., Millar, E., Garland, C., et al (1998) Randomised controlled trial of teaching practice nurses to carry out structured assessments of patients receiving depot antipsychotic injections. British Journal of General Practice, 48, 1845–1848.
Cantle, F. (1997) Management of depot neuroleptics. Practice Nursing, 8, 118–147.
Coutinho, E., Fenton, M. & Quraishi, S. (2000) Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Library, issue 2. Oxford: Update Software
Davis, J., Metalon, L., Watanabe, M., et al (1994) Depot antipsychotic drugs: place in therapy. Drugs, 47, 741–773.
Desai, N. (1999) Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. Advances in Therapy, 16, 78–88.
Eastwood, N. & Pugh, R. (1997) Long-term medication in depot clinics and patients' rights: an issue for assertive outreach. Psychiatric Bulletin, 21, 273–275.
Garavan, J., Browne, S. & Gervin, M. (1998) Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics: attitudes to medication and insight. Comprehensive Psychiatry, 39, 215–219.
Glazer, W. M. & Kane, J. M. (1992) Depot neuroleptics therapy: an underutilized treatment option. Journal of Clinical Psychiatry, 53, 426–433.
Goldbeck, R., Tomlinson, S. & Bouch, J. (1999) Patients' knowledge and views of their depot neuroleptic medication. Psychiatric Bulletin, 23, 467–470.
Greenhalgh, T. (1997) How to Read a Paper. The Basics of Evidence Based Medicine.
London: BMJ Publishing Group.
Hoencamp, E., Knegtering, H., Kooy, J. J. S., et al (1995) Patient requests and attitude towards neuroleptics. Nordic Journal of Psychiatry, 49 (suppl. 35), 47–55.
Jacobsson, L. & Odling, H. (1980) Psykologiska aspekter på depåbehandling vid schizofrena syndrom. Lakartidningen, 77, 3522–3526.
Johnson, D. A. W. (1984) Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. Journal of Clinical Psychiatry, 45, 13–21.
Kendrick, T., Millar, E., Burns, T., et al (1998) Practice nurse involvement in giving depot neuroleptic injections: development of a patient assessment and monitoring checklist. Primary Care Psychiatry, 4, 149–154.
Larsen, E. B. & Gerlach, J. (1996) Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with neuroleptics. Acta Psychiatrica Scandinavica, 93, 381–388.
Lingjaerde, O., Ahlfors, U. G., Bech, P., et al (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica, 334, 1–100.
Pan, P. C. & Tantum, D. (1989) Clinical characteristics, health beliefs and compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic. Acta Psychiatrica Scandinavica, 79, 564–570.
Pereira, S. & Pinto, R. (1997) A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatrica Scandinavica, 95, 464–468.
Poole, I. & Grimes, P. (1998) Depot injections at home or clinic? Letting clients choose. Community Nurse, 4, 15–16.
Quraishi, S. & David, A. (2000) Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders. Cochrane Library, issue 2. Oxford: Update Software
Quraishi, S. & David, A. (2000) Depot fluspirilene for schizophrenia. Cochrane Library, issue 2. Oxford: Update Software
Quraishi, S. & David, A. (2000) Depot haloperidol decanoate for schizophrenia. Cochrane Library, issue 2. Oxford: Update Software
Quraishi, S. & David, A. (2000) Depot perphenazine decanoate and enanthate for schizophrenia. Cochrane Library, issue 2. Oxford: Update Software
Quraishi, S. & David, A. (2000) Depot pipothiazine palmitate and undeclynate for schizophrenia. Cochrane Library, issue 2. Oxford: Update Software
Quraishi, S. & David, A. & Adams, C. E. (2000) Depot bromperidol decanoate for schizophrenia. Cochrane Library, issue 2. Oxford: Update Software
Sandford, T. (1996) Involving users in developing phenothiazine services. In Perspectives in Mental Health Nursing (eds Sandford, T. & Gournay, K.). London: Baillière Tindall.
Simpson, G. M. (1984) A brief history of depot neuroleptics. Journal of Clinical Psychiatry, 45, 3–4.
Singh, V., Hughes, G. & Goh, S. E. (1995) Depot clinic: consumers' viewpoint. Psychiatric Bulletin, 19, 728–730.
Smith, J. A. & Hughes, I. (1999) Non-compliance with anti-psychotic depot medication: users' views on advantages and disadvantages. Journal of Mental Health, 8, 287–296.
University of York NHS Centre for Reviews and Dissemination (1996) Understanding Systematic Reviews of Research on Effectiveness
. York: University of York.
Warren, B. (1998) Developing practice through clinical audit. Journal of Clinical Effectiveness, 3, 151–154.
Wistedt, B. (1995) How does the psychiatric patient feel about depot treatment, compulsion or help?
Nordic Journal of Psychiatry, 49 (suppl. 35), 41–46.